352 related articles for article (PubMed ID: 8539225)
41. Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases.
Burns B; Curry RH; Bell ME
Am J Obstet Gynecol; 1979 Sep; 135(1):109-14. PubMed ID: 474641
[TBL] [Abstract][Full Text] [Related]
42. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).
Miettinen M; Sobin LH; Sarlomo-Rikala M
Mod Pathol; 2000 Oct; 13(10):1134-42. PubMed ID: 11048809
[TBL] [Abstract][Full Text] [Related]
45. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
46. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
47. Comparative analysis of the ERα/ERβ ratio and neurotensin and its high-affinity receptor in myometrium, uterine leiomyoma, atypical leiomyoma, and leiomyosarcoma.
Rodríguez Y; Báez D; de Oca FM; García C; Dorta I; Reyes R; Valladares F; Almeida TA; Bello AR
Int J Gynecol Pathol; 2011 Jul; 30(4):354-63. PubMed ID: 21623207
[TBL] [Abstract][Full Text] [Related]
48. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
49. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
50. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
51. Smooth muscle tumors of the gastrointestinal tract. Expression of ras P21 oncogene product and the association with clinicopathology.
Cai JH; Jiang YK; Zhang YY; Lu GH; Zhang XH; Gao QZ; Zuo LF
Chin Med J (Engl); 1994 Sep; 107(9):683-7. PubMed ID: 7805461
[TBL] [Abstract][Full Text] [Related]
52. C-kit protein expression in uterine and ovarian mesenchymal tumours.
Erdogan G; Bassorgun CI; Pestereli HE; Simsek T; Karaveli S
APMIS; 2007 Mar; 115(3):204-9. PubMed ID: 17367465
[TBL] [Abstract][Full Text] [Related]
53. Abnormal expression of pan-ras, c-myc and tp53 in squamous cell carcinoma of cervix: correlation with HPV and prognosis.
Ngan HY; Cheung AN; Liu SS; Cheng DK; Ng TY; Wong LC
Oncol Rep; 2001; 8(3):557-61. PubMed ID: 11295080
[TBL] [Abstract][Full Text] [Related]
54. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
55. [Expression of nm23 in gastrointestinal smooth muscle tumors and its relation to cell proliferative activity].
Wang Q; Sun W; Zhao Y; Wang M; Qin Y; Fu Y
Zhonghua Wai Ke Za Zhi; 1998 Jul; 36(7):427-9. PubMed ID: 11825432
[TBL] [Abstract][Full Text] [Related]
56. [Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus].
Shi YF; Xie X; Zhao CL
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):201-4, 251. PubMed ID: 8082439
[TBL] [Abstract][Full Text] [Related]
57. The c-myc proto-oncogene in invasive carcinomas of the uterine cervix: clinical relevance of overexpression in early stages of the cancer.
Riou GF; Bourhis J; Le MG
Anticancer Res; 1990; 10(5A):1225-31. PubMed ID: 2173473
[TBL] [Abstract][Full Text] [Related]
58. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall.
Lam MM; Corless CL; Goldblum JR; Heinrich MC; Downs-Kelly E; Rubin BP
Int J Gynecol Pathol; 2006 Jul; 25(3):288-92. PubMed ID: 16810068
[TBL] [Abstract][Full Text] [Related]
59. Cervicovaginal (Papanicolaou) smear findings in patients with malignant mixed Müllerian tumors.
Casey MB; Caudill JL; Salomão DR
Diagn Cytopathol; 2003 May; 28(5):245-9. PubMed ID: 12722119
[TBL] [Abstract][Full Text] [Related]
60. Tissue distribution of TAG-72 in malignant mixed müllerian tumors of the uterus.
Hackett TE; Kaminski P; Olt GJ; Zaino R; Podczaski E
Gynecol Oncol; 1994 Feb; 52(2):165-71. PubMed ID: 7508876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]